CAS: 915769-50-5; 4-Amino-5-Fluoro-3-(6-(4-Methylpiperazin-1-yl)-1H-Benzo[d]Imidazol-2-yl)Quinolin-2(1H)-One 2-Hydroxypropanoate Hydrate

该化合物是一种化学化合物,用作dovitinib的乳盐,一种强力抑制多种受体性强氧气结流酶,包括VEGFR,PDGFR和FGFR.该化合物主要因其在肿瘤学中的潜在治疗应用,特别是在通过抑制肿瘤生长和血管生成来治疗各种癌症方面的潜在治疗应用而进行调查.该化合物的特征是,它能够干扰促进癌症细胞扩散和存活的信号路径.该乳液形态增强了其溶性和生物利用率,使其更适合药物配方.从物理性质来看,它一般是白色到白色固体,其稳定性和溶解性可能因配方和环境条件而不同.与许多制药化合物一样,安全性和功效是通过临床试验来评估的,其使用须得到监管批准.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one DL-lactic acid salt

合成工艺路线路线简述

    📜多韦替尼乳酸盐 以 四氢呋喃,乙酸乙酯 作为反应溶剂,化学反应 24.0H,反应生成 多韦替尼
    参考文献:Wo2006/127926
    标题:Wo2006/127926

    海关参考信息

    专利信息


    专利号:US-10973847-B2
    优先权日:2017-06-30
    标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
    发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

    专利号:WO-2025128098-A1
    优先权日:2023-12-13
    标 题 :Solid oral dosage forms, kits, and methods of using the same
    发明人:LI YING; LANGER ROBERT; TRAVERSO CARLO
    权利人:MASSACHUSETTS INST TECHNOLOGY; BRIGHAM & WOMENS HOSPITAL INC
    摘要:Provided herein are solid oral dosage forms, methods, and kits useful, e.g, for the extension of the residence time of active pharmaceutical agents in vivo by the synthesis of a polymer in situ in a subject. In particular, the solid oral dosage forms, methods, and kits disclosed herein are particularly useful for drugs that require more than once daily administration (e.g, drugs that have short half-lives).

    专利号:US-9365532-B1
    优先权日:2011-02-14
    标题:Synthesis, composition and use of novel therapeutic and cosmetic Schiff base products formed by reaction of a carbonyl containing moeity with a transimination nucleophilic catalyst and the use of transimination nucleophilic catalysts to increase the rate at which carbonyl containing therapeutic and cosmetic actives form Schiff base products with biological amines
    发明人:ISAACMAN STEVEN
    权利人:ISAACMAN STEVEN; NANOMETICS LLC
    摘要:The present invention relates to the synthesis, composition and use of novel moieties formed by reacting a transimination nucleophilic catalyst, molecular or polymeric, with carbonyl-containing therapeutic or cosmetic moieties. The resultant Schiff base product is highly reactive towards transimination with a biological amine. The catalyst and carbonyl-containing moiety can be molecular or polymeric, and the resultant chemical and physical properties of the Schiff base products can be engineered by appropriate selection of said catalyst. The present invention also relates to the synthesis, composition and use of novel moieties that are used as actives in sunless tanning preparations. The present invention also relates to the use of transimination nucleophilic catalysts to increase the rate at which a carbonyl-containing moiety reacts with a biological amine. The present invention also relates to the use of transimination nucleophilic catalysts to increase the rate and efficacy of commercial sunless tanning preparations. Improvements on stability and efficacy of said preparations are disclosed. While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims. Accordingly, the present invention should not be limited to the embodiments as described above, but should further include all modifications and equivalents thereof within the spirit and scope of the description provided herein.

    专利号:US-2019031650-A1
    优先权日:2016-01-29
    标 题 :Dna alkylation and cross-linking agents as compounds and payloads for targeted therapies
    发明人:HERZON SETH; HEALY ALAN; CRAWFORD JASON; VIZCAINO MARIA; NIKOLAYEVSKIY HERMAN
    权利人:UNIV YALE
    摘要:The present invention is directed to compounds related to precolibactin pharmaceutical compositions based upon these compounds and methods of synthesis which are employed to provide intermediates and final compounds, which are principally alkylating agents and anticancer compounds. The chemical synthetic approach disclosed facilitates the synthesis of numerous precolibactin analogs which can be used in the treatment of cancer.

    专利号:US-2007021436-A1
    优先权日:2005-06-10
    标 题 :Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis

    专利号:CA-2611219-A1
    优先权日:2005-06-10
    标题 :Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators and related methods of synthesis

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Pilié P, Hasanov E, Matin SF, Woodson AHH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E. Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget. 2018 May 4;9(34):23390-23395. doi: 10.18632/oncotarget.25171. eCollection 2018 May 4.
    2: Choi YJ, Kim HS, Park SH, Kim BS, Kim KH, Lee HJ, Song HS, Shin DY, Lee HY, Kim HG, Lee KH, Lee JL, Park KH. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). Cancer Res Treat. 2018 Jan 2. doi: 10.4143/crt.2017.438. [Epub ahead of print] doi: 10.1007/s00280-017-3469-4. Epub 2017 Nov 3. doi: 10.1186/s40169-017-0169-y.
    5: Landberg N, Dreimane A, Rissler M, Billström R, Ågerstam H. Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. Eur J Haematol. 2017 Nov;99(5):442-448. doi: 10.1111/ejh.12957. Epub 2017 Oct 4. doi: 10.1038/bjc.2017.290. Epub 2017 Aug 29.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知